Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study

Loading...
Thumbnail Image
File version

Version of Record (VoR)

Author(s)
Dzudie, Anastase
Njume, Epie
Abanda, Martin
Aminde, Leopold
Hamadou, Ba
Dzekem, Bonaventure
Azabji, Marcel
Doualla, Marie Solange
Ngowe, Marcelin
Kengne, Andre P
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2020
Size
File type(s)
Location
Abstract

Background: More than 80% of premature deaths due to cardiovascular disease (CVD) occur in low- and middle-income countries. However, access to, and affordability of medications remain a challenge in these countries. Objective: To assess the availability, cost and affordability of essential cardiovascular medicines in the South West region of Cameroon. Methods: In an audit of 63 medicine outlets, twenty-six essential medicines were surveyed using the World Health Organisation (WHO) /Health Action International methodology. Availability, costs and the ratio of the median price to the international reference price were evaluated in public, confessional, private facility medicine outlets, and community pharmacies. Affordability was assessed by calculating the number of days' wages it will cost the lowest-paid unskilled government worker to purchase a month worth of chronic treatment. Findings: Availability ranged from 25.3% (public facility outlets) to 49.2% (community pharmacies) for all medicines. This was higher in urban and semi-urban compared to rural outlets. Cost of medicines was highest in community pharmacies and lowest in public facility outlets. Aspirin, digoxin, furosemide, hydrochlorothiazide and nifedipine were affordable (cost a day's wage or less). Medicines for heart failure and dyslipidaemia (beta blockers, angiotensin converting enzyme inhibitors and statins) required 2-5 days and 6-13 days wages respectively for one month of chronic treatment. Conclusion: Overall availability of CVD essential medicines was lower than WHO recommendations, and medicines were largely unaffordable. While primary prevention is pivotal, improving availability and affordability of medicines especially for public facilities would provide additional benefit in curbing the CVD burden.

Journal Title

PLoS ONE

Conference Title
Book Title
Edition
Volume

15

Issue

3

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

© 2020 Dzudie et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Item Access Status
Note
Access the data
Related item(s)
Subject

Biomedical and clinical sciences

Persistent link to this record
Citation

Dzudie, A; Njume, E; Abanda, M; Aminde, L; Hamadou, B; Dzekem, B; Azabji, M; Doualla, MS; Ngowe, M; Kengne, AP, Availability, cost and affordability of essential cardiovascular disease medicines in the south west region of Cameroon: Preliminary findings from the Cameroon science for disease study, PLoS ONE, 2020, 15 (3), pp. e0229307:1-e0229307:12

Collections